,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,28386,3,4,,123083186,13730,Unspecified,,,,,Partition coefficient in 1-octanol and 10 mM aqueous potassium phosphate buffer at pH 7.4,Other,2754702.0,
1,31247,3,7,,123083186,13730,Unspecified,,,,,Binding affinity determined on Adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.,Other,7707320.0,
2,32065,8,1,,123083186,13730,Unspecified,,,100.0,ED50,Protection of ATH8 cells against the cytopathic effect of HIV.,Confirmatory,3497272.0,
3,32066,8,1,,123083186,13730,Unspecified,,,100.0,ID50,Required dose to reduce viability of normal uninfected ATH8 cells.,Confirmatory,3497272.0,
4,32353,9,2,,123083186,13730,Active,,,23.3,Ki,Affinity for the Adenosine A1 receptor in the presence of GTP (A1+GTP) by using [3H]-DPCPX as radioligand,Confirmatory,7562934.0,
5,33205,4,6,,123083186,13730,Unspecified,,,,,Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat Adenosine A3 receptor,Other,7707320.0,
6,33765,4,6,,123083186,13730,Unspecified,,,,,Binding affinity determined on Adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand.,Other,7707320.0,
7,33813,6,4,,123083186,13730,Active,,,31.0,Km,Kinetic constant (Km) for the deamination of compound by adenosine deaminase,Confirmatory,10673097.0,
8,33830,5,6,,123083186,13730,Unspecified,,,,,Ratio of kinetic constant (Vmax/Km) for the deamination of compound by adenosine deaminase,Other,10673097.0,
9,33834,4,8,,123083186,13730,Unspecified,,,,,Kinetic constant (relative Vmax) for the deamination of compound by adenosine deaminase,Other,10673097.0,
10,33836,4,8,,123083186,13730,Unspecified,,,,,Kinetic constant (Vmax) for the deamination of compound by adenosine deaminase,Other,10673097.0,
11,34585,9,5,,123083186,13730,Active,2833201.0,64532.0,15.0,IC50,Compound was evaluated for inhibition of adenylate cyclase from rat brain,Confirmatory,14971900.0,
12,68252,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
13,68253,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
14,68254,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
15,68255,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
16,68256,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
17,68257,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM),Other,8176708.0,
18,81069,7,1,,123083186,13730,Unspecified,,,,,Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells.,Other,3172142.0,
19,81438,8,1,,123083186,13730,Unspecified,,,100.0,ED50,Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.,Confirmatory,3172142.0,
20,81802,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against (HIV-1) in MT-4 cells Value in parentheses is inhibitory concentration for cell growth (MT-4),Other,1335077.0,
21,83196,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (AD-169) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
22,83197,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (Davis) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
23,83198,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce TK Varicella Zoster virus (VZV) (07/1) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
24,83199,6,3,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Varicella Zoster virus (VZV) (Oka) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
25,84402,6,3,,123083186,13730,Unspecified,,,,,Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
26,85279,6,3,,123083186,13730,Unspecified,,,,,Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
27,86485,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Respiratory syncytial virus (RSV) (Long) induced cytopathicity in human carcinoma cells (HeLa),Other,8176708.0,
28,86488,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human carcinoma cells (HeLa),Other,8176708.0,
29,105750,4,4,,123083186,13730,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration,Other,3497272.0,
30,105753,4,4,,123083186,13730,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration,Other,3497272.0,
31,105756,3,4,,123083186,13730,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration.,Other,3497272.0,
32,105762,4,4,,123083186,13730,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration,Other,3497272.0,
33,105765,3,4,,123083186,13730,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration; Range is 10-40,Other,3497272.0,
34,105766,4,4,,123083186,13730,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration,Other,3497272.0,
35,105779,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Influenza A virus (Ishikawa) induced cytopathicity in Madin-Darby canine kidney cells (MDCK),Other,8176708.0,
36,105780,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce influenza B virus (Singapore) induced cytopathicity in Madin-Darby canine kidney cells (MDCK),Other,8176708.0,
37,105782,6,2,,123083186,13730,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of Madin-Darby canine kidney cells (MDCK),Other,8176708.0,
38,202930,6,2,,123083186,13730,Active,,,0.03,IC50,Compound along with 10 uM of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was tested against mouse lymphoma T-cells,Confirmatory,3874961.0,
39,202931,6,2,,123083186,13730,Unspecified,,,180.0,IC50,Compound evaluated for the inhibitory concentration of S49 Mouse Lymphoma T-cells,Confirmatory,3874961.0,
40,210695,8,1,,123083186,13730,Unspecified,,,1000.0,ID50,Compound was tested for inhibit phosphorylation of [3H]-D-T catalyzed by HSV 1 thymidine kinase,Confirmatory,1331461.0,
41,210718,3,8,,123083186,13730,Inactive,,,,,Compound was tested for inhibit phosphorylation of [3H]-D-T catalyzed by human thymidine kinase; Inactive at 1 uM concentration,Other,1331461.0,
42,220033,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against coxsackie B4 in Vero cell culture lines,Other,1335077.0,
43,220034,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in HeLa cell culture lines,Other,1335077.0,
44,224916,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines,Other,1335077.0,
45,225768,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against polio virus type 1 in HeLa cell culture lines,Other,1335077.0,
46,226341,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against sindbis virus in Vero cell culture lines,Other,1335077.0,
47,228408,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against reovirus type 1 in Vero cell culture lines,Other,1335077.0,
48,228985,6,2,,123083186,13730,Unspecified,,,,,Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines,Other,1335077.0,
49,229026,6,3,,123083186,13730,Unspecified,,,,,Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
50,229234,6,2,,123083186,13730,Unspecified,,,,,"Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines,",Other,1335077.0,
51,229236,6,3,,123083186,13730,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
52,342012,7,1,,123083186,13730,Unspecified,122943346.0,,,Km,Activity of Staphylococcus aureus CCM 885 recombinant deoxyadenosine kinase,Confirmatory,17526755.0,
53,342013,10,1,,123083186,13730,Unspecified,122943346.0,,,,Ratio of kcat to Km for Staphylococcus aureus CCM 885 recombinant deoxyadenosine kinase,Other,17526755.0,
54,344442,7,1,,123083186,13730,Unspecified,118447.0,1633.0,,Km,Activity of human wild type deoxycytidine kinase in presence of ATP,Confirmatory,18570408.0,
55,344443,7,1,,123083186,13730,Unspecified,118447.0,1633.0,,Km,Activity of human wild type deoxycytidine kinase in presence of UTP,Confirmatory,18570408.0,
56,344444,7,1,,123083186,13730,Unspecified,118447.0,1633.0,,,Ratio of Kcat for human wild type deoxycytidine kinase to Km for human wild type deoxycytidine kinase in presence of ATP,Other,18570408.0,
57,344445,7,1,,123083186,13730,Unspecified,118447.0,1633.0,,,Ratio of Kcat for human wild type deoxycytidine kinase to Km for human wild type deoxycytidine kinase in presence of UTP,Other,18570408.0,
58,344446,7,1,,123083186,13730,Unspecified,,,,Km,Activity of human deoxycytidine kinase C4S mutant in presence of ATP,Confirmatory,18570408.0,
59,344447,7,1,,123083186,13730,Unspecified,,,,Km,Activity of human deoxycytidine kinase C4S mutant in presence of UTP,Confirmatory,18570408.0,
60,344448,7,1,,123083186,13730,Unspecified,,,,,Ratio of Kcat for human deoxycytidine kinase C4S mutant to Km for deoxycytidine kinase C4S mutant in presence of ATP,Other,18570408.0,
61,344449,7,1,,123083186,13730,Unspecified,,,,,Ratio of Kcat for human deoxycytidine kinase C4S mutant to Km for deoxycytidine kinase C4S mutant in presence of UTP,Other,18570408.0,
62,353131,3,3,,123083186,13730,Unspecified,,,,,Inhibition of penicillin-resistant Streptococcus pneumoniae 159 recombinant MurM at 1 mM by liquid scintillation counting,Other,19356937.0,
63,369218,3,3,,123083186,13730,Unspecified,,,,,Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks,Other,17606676.0,
64,372435,4,3,,123083186,13730,Inactive,,,,,Inhibition of Trypanosoma brucei brucei 427 P1 transporter-mediated [3H]adenosine uptake by fluid scintillation counting in presence of 100 uM adenine,Other,17698622.0,
65,372436,6,2,,123083186,13730,Active,,,0.23,Ki,Inhibition of Trypanosoma brucei brucei 427 P2 transporter-mediated [3H]adenosine uptake by fluid scintillation counting in presence of 100 uM inosine,Confirmatory,17698622.0,
66,445467,5,3,,123083186,13730,Active,,,11.0,Ki,Displacement of [3H]adenine from adenine 1 receptor in rat brain cortical membrane by liquid scintillation counting,Confirmatory,19731917.0,
67,445471,5,2,,123083186,13730,Unspecified,,,100.0,Ki,Displacement of [3H]adenine from adenine 1 receptor in HEK293 cells by liquid scintillation counting,Confirmatory,19731917.0,
68,445472,3,4,,123083186,13730,Unspecified,,,,,Inhibition of [3H]adenine binding to adenine 1 receptor in HEK293 cells at 100 uM by liquid scintillation counting,Other,19731917.0,
69,445473,3,4,,123083186,13730,Unspecified,,,,,Selectivity ratio of Ki for adenine 1 receptor in HEK293 cells to Ki for adenine 1 receptor in rat brain cortical membrane,Other,19731917.0,
70,485290,1,1,,26755583,13730,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
71,504339,1,1,,26755583,13730,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
72,504444,1,1,,26755583,13730,Inconclusive,224028257.0,4780.0,25.929000000000002,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
73,504648,1,1,,26755583,13730,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
74,504845,1,1,,26755583,13730,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
75,504847,1,1,,26755583,13730,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
76,504891,1,1,,26755583,13730,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
77,517826,1,4,,123083186,13730,Unspecified,,,,,Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 10 ug/ml,Other,20857959.0,
78,517832,1,4,,123083186,13730,Unspecified,,,,,Antiviral activity against HBV assessed as inhibition of viral DNA replication at 10 ug/mL,Other,20857959.0,
79,517842,4,3,,123083186,13730,Inconclusive,,,,CC50,Cytotoxicity against HuH7 cells,Confirmatory,20857959.0,
80,540267,1,1,,26755583,13730,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
81,540317,1,1,,26755583,13730,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
82,588453,1,1,,26755583,13730,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
83,588456,1,1,,26755583,13730,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
84,588579,1,1,,26755583,13730,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
85,588590,1,1,,26755583,13730,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
86,588795,1,1,,26755583,13730,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
87,588855,1,1,,26755583,13730,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
88,588856,1,1,,26755583,13730,Inactive,,,1.2589,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
89,602310,1,2,,26755583,13730,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
90,602332,1,1,,26755583,13730,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
91,624178,1,1,,26755583,13730,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
92,624202,1,1,,26755583,13730,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
93,624263,1,1,,26755583,13730,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
94,624263,1,1,,26755583,13730,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
95,624414,1,1,,26755583,13730,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
96,651965,1,1,,26755583,13730,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
97,652106,1,1,,26755583,13730,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
98,662565,1,3,,123083186,13730,Unspecified,,,,,Growth inhibition of Trichomonas vaginalis T1 at 100 uM after 24 hrs by hemocytometry,Other,22579483.0,
99,686978,1,1,,26755583,13730,Inconclusive,79154014.0,55775.0,19.9526,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
100,686979,1,1,,26755583,13730,Inconclusive,79154014.0,55775.0,7.0795,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
101,720579,2,1,,26755583,13730,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
102,720580,1,1,,26755583,13730,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
103,977599,1,1,,123083186,13730,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
104,977602,1,2,,123083186,13730,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
105,1122015,1,1,,123083186,13730,Unspecified,,,250.0,IC50,Cytotoxicity against rat L6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,,
106,1122016,1,1,,123083186,13730,Unspecified,,,250.0,IC50,Cytotoxicity against human HaCaT cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,,
107,1122017,1,2,,123083186,13730,Unspecified,,,250.0,IC50,Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,,
108,1122018,1,1,,123083186,13730,Unspecified,,,250.0,IC50,Cytotoxicity against rat C6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,,
109,1122019,1,1,,123083186,13730,Unspecified,,,250.0,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,,
110,1259407,1,1,,363899732,13730,Inactive,,,,,CCRIS mutagenicity studies,Other,,
111,1259408,1,1,,363895945,13730,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
